Heart failure & cardiomyopathies
Personalized Lifetime Prediction of Survival and Treatment Benefit in Patients with Heart Failure with Reduced Ejection Fraction: The LIFE-HF Model
Authors' conclusion
The LIFE-HF model enables estimation of lifelong overall and HF hospitalization-free survival, and (lifetime) treatment benefit for individual patients with HFrEF.
Study context
- Population
- Patients with heart failure with reduced ejection fraction (HFrEF) (development: PARADIGM-HF and ATMOSPHERE trials; validation: SwedeHF registry, ASIAN-HF registry, DAPA-HF trial)validation n = 51,286
- Participants
- 15,415 patients
- Outcome
- CV death, HF hospitalization or CV death, and non-CV mortality
Methodological detailsexternal validation
- External validation
Performance
As reported in the abstract
Model performance in external validation
C-statistics
0.65-0.74
Further findings
Estimated benefit of combined MRA, SGLT2 inhibitor and ARNI in development cohort
- Additional years of overall survival, median (IQR 1.7-3.7)
- 2.5
- Additional years of heart failure (HF) hospitalization-free survival, median (IQR 2.4-5.5)
- 3.7
Original publication
Personalized Lifetime Prediction of Survival and Treatment Benefit in Patients with Heart Failure with Reduced Ejection Fraction: The LIFE-HF Model. Eur J Heart Fail. Published 18 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →